



(REVIEW ARTICLE)

Autoimmune diseases in children and anesthesia

Maria I Dalamagka *

Department of Anesthesiology, General Hospital of Larisa, Greece.

Magna Scientia Advanced Biology and Pharmacy, 2025, 14(01), 045-052

Publication history: Received on 26 December 2024; revised on 13 February 2025; accepted on 16 February 2025

Article DOI: <https://doi.org/10.30574/msabp.2025.14.1.0022>

Abstract

Autoimmune diseases in children may be linked to genetic, environmental, and hormonal factors. It's estimated that 5% of children worldwide have at least one autoimmune condition, with many experiencing multiple autoimmune challenges. Around 80 autoimmune diseases are present. However, autoimmune diseases in children are rare. When they occur they can be challenging to diagnose and difficult to treat. Advances in our knowledge of the immune system are uncovering connections between inflammation and many different diseases. All autoimmune diseases have relapsing and remitting tendencies. Autoimmune diseases can affect almost any part of the body, though they often target connective tissues (skin, muscle and joints). Symptoms can range from fatigue and mild rashes to rare, serious side effects, like seizures. Diagnosis can be difficult, because many symptoms tend to come and go and are frequently nonspecific. They occur in different kinds of autoimmune diseases as well as other types of illnesses, like infection and cancer. Autoimmune diseases occur most often in females by a 3-to-1 margin over males. Organ-specific disorders (also called localized) focus on one organ or a specific type of tissue: Addison's disease affects the adrenal glands; Autoimmune hepatitis affects the liver; Crohn's disease affects the gastrointestinal tract; Multiple sclerosis (MS) affects the central nervous system; Type 1 diabetes affects the pancreas; Ulcerative colitis affects the gastrointestinal tract. Non-organ-specific disorders (also called systemic) cause problems throughout the body: Juvenile dermatomyositis affects the skin and muscles; Juvenile idiopathic arthritis affects the joints and sometimes the skin and lungs; Lupus affects the joints, skin, liver, kidneys, heart, brain, and other organs; Scleroderma affects the skin, joints, intestine, and sometimes the lungs. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are rare neurobehavioral disorders in children. Affected children may have a diverse array of perioperative manifestations including compulsive behavior, agitation, and abnormal movements. Intravenous anesthetics have anti-inflammatory properties, which in most septic cases are useful for patients. The anti-inflammatory effects of ketamine may be related to the suppression of TNF production by macrophage in the presence of bacteria. Propofol inhibits the phagocytosis and chemotaxis of human monocytes through GABAA receptors. Inhalational anesthetics, in a dose-dependent manner, suppress cytokine release, reduces lymphocyte proliferation, induce apoptosis of the lymphocytes, and inhibits the function of neutrophils. Inhalational anesthetics influence the endocrine response from the hypothalamus-pituitary-adrenal axis and indirectly through the secretions of hormones, such as glucocorticoids and catecholamines. Long-term administration of general anesthesia drugs, due to their effects on cytokines, can lead to disease progression in patients with immune deficiency.

Keywords: Autoimmune diseases; General anesthesia; Children; Immune system; PANDAS; OCD

1. Introduction

The production of antibodies to streptococcal antigens associated with the M-protein of Group A beta hemolytic streptococcus (GABHS) has been shown to cross-react with epitopes on neuronal tissue. It has been postulated that the pathogenesis of Sydenham's chorea results from immune complex disease produced by nondestructive anti-streptococcal antibodies that localize to the basal ganglia and striatal areas of the brain. Structural and functional

* Corresponding author: Maria I Dalamagka

neuroimaging studies have demonstrated abnormalities of the basal ganglia structures and their related corticostriato-thalamocortical circuitry in the pathobiology of obsessive compulsive disorder (OCD). The PANDAS subgroup is identified by five clinical criteria: presence of OCD and/or tic disorder; prepubertal symptom onset; episodic course characterized by acute, severe onset and dramatic symptom exacerbations; neurological abnormalities (e.g., choreiform movements) present during symptom exacerbations; temporal relation between GABHS infections and symptom exacerbations. The major distinguishing feature of the PANDAS subgroup is the temporal association between neuropsychiatric symptom exacerbations and GABHS infections. Anesthetic Implications: PANDAS are rare and affected children have significant anesthetic implications. The abnormal behavior and movement of children with PANDAS are real challenge to anesthesiologists. We have described the first case in anesthesia literature of a patient with PANDAS who required anesthesia for a series of therapeutic plasmapheresis. The children usually have motor or vocal tics, obsessions, and/or compulsions. Often communication with them is a major problem. In addition to these symptoms, children may also become moody, irritable or show concerns about separating from parents. In our patient, premedication with oral ketamine and midazolam worked well to separate the patient from his parents and gain an intravenous access. Propofol infusion at usual doses provided optimum sedation during plasmapheresis and the recovery from propofol was favorable. With frequent plasmapheresis, there is a potential for coagulopathy from washout/dilution of plasma clotting factors. Evaluating coagulation status, especially after the first few plasmaphereses may identify patients at risk of bleeding. In conclusion, we described our anesthetic management of a case of PANDAS in a young boy who underwent a series of therapeutic plasmapheresis. Anesthesiologists should be aware of the abnormal behavior and movements with this disorder and potential anesthetic implications. Atopic dermatitis is one of the most common skin disorders in childhood, and general anaesthesia has a risk of developing potential complications in various organs and anaphylaxis and allergies. However, the relationship between exposure to general anaesthesia and atopic dermatitis remains unknown. General anaesthesia (GA) has a risk of developing potential complications in various organs and anaphylaxis and allergies. General anaesthesia could affect various immune responses, including Th1 and Th2 immunity, which might also affect cells that play an important role in the pathogenesis of atopic dermatitis. The number of patients undergoing GA in the paediatric population is increasing and thus interest in whether GA could be a risk factor for various diseases has increased. In particular, previous studies revealed that exposure to GA in early childhood and multiple exposures increased the risk of developmental delay and attention deficit hyperactivity disorder. Conversely, autistic disorders or learning disabilities were not associated with a single exposure to GA. Also, it has been reported that exposure to GA in early life reduced the risk of asthma, allergic rhinitis, and AD. Congenital myasthenic syndromes are genetically, mainly recessive, transmitted disorders. This group is clinically very heterogeneous, children present shortly after birth with a feeding problem and muscular hypotonia. As a severe symptom is respiratory insufficiency is well described and children often need artificial ventilation. A few children respond to therapy with acetylcholinesterase-blockers. The defect could be located presynaptic (eg. CholinacetylTransferase Defect CHAT), synaptic (eg. mutations in the gene encoding for Collagen Q COLQ) and postsynaptic (eg. disturbances in fast or slow channels in acetylcolinrezeptors or mutations in the gene encoding for the Rapsyn gene). A special feature in CHAT defects are recurrent apnea in children suffering from simple infectious diseases. These children require fast intubation and artificial ventilation. Transient Neonatal Myasthenia gravis occurs in approximately 12% of the newborns of mothers with MG and improves within the first weeks of life as the antibody concentration decreases. The first signs are often muscular hypotonia, feeding problems and respiratory [1-24].

2. Autoimmune diseases

The exact causes of autoimmune conditions in children are not fully understood. Research suggests there may be a complex interplay between environmental factors, genetics, and increased intestinal permeability. A disease is defined as autoimmune if the tissue injury is caused by an adaptive immune response to self-antigen. Development of the disease by transferring the active component of the immune response to an appropriate recipient (usually an animal model, or in some instances materno-fetal transfer of autoantibody) is the best proof that a disease is caused by autoimmunity. Autoimmune diseases can be considered on a continuum between those which are organ specific, and those which are non-organ specific. There are over 100 identified autoimmune conditions. Some commonly known in children include: Type 1 diabetes, the immune system affects the beta cells of the pancreas, impacting insulin production; Celiac disease, the immune system reacts to gliadin, a protein in gluten-containing foods, affecting the small intestine lining; Juvenile idiopathic arthritis, the immune system produces markers that primarily affect the joints; Pediatric lupus, the immune system targets various tissues, including the lungs, skin, and kidneys. Autoantibodies are commonly regarded as being intrinsically involved in the tissue injury associated with autoimmune diseases. Whilst this may be true in a number of important examples (e.g. systemic lupus erythematosus (SLE), Goodpasture's disease, and myasthenia gravis), this is not true of all autoimmune diseases. For example, autoantibodies may form secondary to the tissue damage associated with the underlying disease (e.g. cardiac antibodies produced after myocardial infarction). Corticosteroids, cytotoxic drugs and other immunosuppressant agents are an important part of the therapeutic approach to many non-malignant autoimmune disorders. Thus, treatment protocols for these diseases in pediatrics are often based on adult practice, but

despite the similarities in disease processes, the most widely used treatments have different effects in children. Some of the side effects of chronic steroid use, including linear growth deceleration, bone demineralization, and chronic weight issues, are more consequential in children than in adults. Although steroids remain a cornerstone of therapy in JDM and are useful in many cases of CIDP and JMG, other immunomodulatory therapies with similar efficacy may be used more frequently. Early treatment with intravenous immunoglobulin (IVIG) or plasma exchange (PE) is recommended for any child with Guillain-Barré syndrome who has difficulty ambulating. Azathioprine is the most widely used steroid-sparing therapy in childhood CIDP (Chronic inflammatory demyelinating polyradiculoneuropathy). Patients with juvenile myasthenia gravis (JMG) can be offered three main categories of disease-modifying therapy: acetylcholinesterase inhibitors (AChE-I), medical immunomodulation or immunosuppression, and surgical intervention (thymectomy). Corticosteroids (prednisone, prednisolone, methylprednisolone) are effective immunosuppressants with good evidence for their efficacy in MG. Methotrexate is often used as an alternative immunosuppressant agent in adults with MG who are unable to tolerate azathioprine. Cyclophosphamide therapy has been used for severe, treatment-resistant adult MG. Rituximab has been used with promising results in adults with severe, refractory MG. Plasma exchange (PE) is an alternative to IVIG for treating acute exacerbations. The immune system relies on a large number of genes for its normal development. In children affected by combined immunodeficiency (CID), a defect in one or more of these genes results in the absence or malfunction of a protein necessary for normal functioning of the immune system. Different types of CID are named based on the particular protein or gene that is affected. Some of the better-known types include Wiskott-Aldrich syndrome, DOCK8 deficiency and recombination activating gene (RAG) deficiency. Some live vaccines might need to be avoided, particularly BCG, rotavirus, measles/mumps/rubella (MMR) and chickenpox (VZV). Haematopoietic stem cell transplantation In some cases, haematopoietic stem cell transplant (HSCT) (including bone marrow transplant, BMT) offers the potential for long-term cure of CID. This treatment is most well-established for defined types of CID that are known to be life-limiting because of predictably severe complications. Gene therapy aims to correct the underlying genetic abnormality by replacing the faulty gene in immune cells with a normal copy. The commonest condition affecting thymus development is called 22q11 deletion syndrome (also known as DiGeorge syndrome). In the small fraction (<1%) of DiGeorge patients whose thymus is completely missing, thymic transplant may need to be considered [25-63].

3. Anesthesia - Anesthetic Drugs and immune system

General anesthesia, which is a drug-induced deliberate state, is the most commonly used strategy in anesthesia care. There are various drugs to ensure unconsciousness, analgesia, amnesia, and loss of reflexes of the autonomic nervous system. General anesthesia usually induces using intravenous anesthetics, inhalational (volatile) anesthetics or a combination of both. Also, opioids and benzodiazepines are often used as adjuvants in general anesthesia. In some cases, ventilation of the patients should be controlled. Anesthesia and drugs that administer to induce the anesthesia, affect the immune system, mainly immune cells, during the perioperative period. The effects of anesthesia on B-lymphocytes, T-lymphocytes, NK cells, macrophages, erythrocytes, and leukocytes is well documented. Anesthesia affects the pro-inflammatory and anti-inflammatory cytokines' secretion. The main Pro-inflammatory cytokines include IL-6, IL-8, IL-1, and tumor necrosis factor- α (TNF- α). The main anti-inflammatory cytokine includes IL-10. The levels of interferon Gamma (IFN- γ) and TNF are changed by general anesthesia. Evaluation of the effects of general anesthesia agents on the immune system helps to improve the management of anesthesia. The most common method to produce general anesthesia is the intravenous anesthesia (IV anesthesia). Sodium thiopental, propofol, and ketamine are examples of drugs which commonly use in IV anesthesia. Ketamine and sodium thiopental reduce the number of T-helper cells and NK cell activities and increase the T-inhibiting cells. Sodium thiopental and ketamine inhibit the release of IL-1, IL-6, TNF- α , and IL-8. It is well-documented that low dose ketamine, as an N methyl-D-aspartate (NMDA) receptors antagonist, reduces the lifetime of IL-6. In addition, these drugs increase the level of IL-10. However, according to the results reported by Song et al., ketamine inhibits the production of anti-inflammatory cytokines. Sodium thiopental is a rapid induction intravenous anesthetic agent which affects the GABA- A receptors that their presence in immune cells is confirmed. In a study, the effect of propofol and sodium thiopental on Th1/Th2 balance is compared by measuring the levels of IFN- γ , IL-4, and IL-2. Compared to propofol, sodium thiopental reduce the concentration of IFN- γ and IL-4 without affecting the concentration of IL-2. Propofol (2,6-diisopropylphenol) is a commonly used intravenous anesthetic agent. Besides, it uses for maintenance of general anesthesia and sedation in the intensive care unit. Propofol causes rapid induction of and recovery from anesthesia. This drug has anti-oxidant and anti-inflammatory characteristics. Information about whether anesthesia with propofol increases or decreases the IL-6 levels is controversial. Propofol in vitro inhibits IL-6 production by stimulated lipoproteins. The study conducted by Gonzalez-Correa et al. reported that propofol decreased the concentration of IL-1, TNF- α , and IL-6 cytokines. Propofol increases the concentration of IL-10. A higher concentration of anti-inflammatory cytokines in patients who received propofol is the reason for its anti-inflammatory properties. Jin et al. reported that Injection of high dose propofol increased the ratio of IFN- γ /IL-4, while low dose propofol did not change the concentration of the cytokine. Volatile anesthetics can inhibit the release of IFN in animals, reduce the number of NK cells, and the production of cytokines in the human body.

Desflurane increases the number of neutrophil cell and pro-inflammatory cytokines expression in alveolar macrophages. Desflurane produces more pro-inflammatory responses compared to sevoflurane. Evidence suggests that opioids affect the immune system, although the results are contradictory. Both the suppressive and stimulant effects of the opioids on the immune system are reported by various studies. Opioids cause a significant reduction in the concentration of TNF- α , IL-1, and IL-6. Morphine produces TGF- β by stimulating lymphocytes, monocytes, and macrophages. These effects are mainly the result of long-term treatment, which leads to an increase in the concentration of IL-4 and IL-5 as well as the reduction of IL-2 and IFN- γ . Fentanyl exhibited cytotoxicity against NK cells. It is found that morphine, remifentanyl, fentanyl, methadone, and codeine alter the immune system more than oxycodone, hydrocodone, and tramadol. Remifentanyl decreases IFN- γ concentrations. IL-6, TNF, IL-10, and IL-2 concentrations do not change during treatments with remifentanyl or fentanyl. Midazolam is more common than other benzodiazepines, because if administered intravenously causes less pain, and it's a short-acting drug compared to others. Midazolam can inhibit the production of IL-2 and IL-8 and produces an immunosuppression effect. Midazolam can inhibit the activity of TNF- α [64-81].

4. Discussion

One of the ventilation methods during general anesthesia is controlled ventilation. Controlled ventilation, through damaging alveolar cells and mechanical stress, suppresses the stability of the ventilation/perfusion ratio, which results in the release of inflammatory mediators and worsening of the gas exchange during the postoperative period. The other factor that causes lung tissue damage and increases the release of cytokines is hypoxia during surgeries. Sevoflurane reduces the inflammatory response during one-lung ventilation in chest surgery and may be preferable in patients who the level of their pro-inflammatory cytokines is more than expected. Treatment of childhood autoimmune disorders is based upon published prospective and retrospective cohort studies, expert opinion, pediatric randomized controlled trials (particularly for Guillain-Barré syndrome and dermatomyositis), and extrapolation of results from adult studies. Early diagnosis and initiation of treatment can significantly reduce long-term morbidity for these diseases. In addition to affecting quality of life, pediatric autoimmune conditions may increase the risk of various health issues, including cardiometabolic concerns, cancer, and mental health challenges. Conventional treatments can provide some relief but may not address all underlying factors of autoimmunity.

5. Conclusion

Autoimmune neuromuscular disorders in childhood include Guillain-Barré syndrome and its variants, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), juvenile myasthenia gravis (JMG), and juvenile dermatomyositis (JDM), along with other disorders rarely seen in childhood. Intravenous anesthetics have anti-inflammatory properties, which in most septic cases are useful for patients. The anti-inflammatory effects of ketamine may be related to the suppression of TNF production by macrophage in the presence of bacteria. Propofol inhibits the phagocytosis and chemotaxis of human monocytes through GABAA receptors. Inhalational anesthetics, in a dose-dependent manner, suppress cytokine release, reduces lymphocyte proliferation, induce apoptosis of the lymphocytes, and inhibits the function of neutrophils. Inhalational anesthetics influence the endocrine response from the hypothalamus-pituitary-adrenal axis and indirectly through the secretions of hormones, such as glucocorticoids and catecholamines. Long-term administration of general anesthesia drugs, due to their effects on cytokines, can lead to disease progression in patients with immune deficiency. Many autoimmune diseases share common pathogenic mechanisms. However, there are limited studies quantifying the coexistence of autoimmune diseases.

References

- [1] Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: a review. *Pediatr Dermatol* 2019; 36: 66–71.
- [2] Kantor R, Thyssen J, Paller A, Silverberg J. Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta-analysis, and recommendation for uniform use of 'atopic dermatitis'. *Allergy* 2016; 71: 1480–1485.
- [3] Çetinkaya PG, Şahiner ÜM. Childhood atopic dermatitis: current developments, treatment approaches, and future expectations. *Turk J Med Sci* 2019; 49: 963–984.
- [4] Ha J, Lee SW, Yon DK. Ten-Year trends and prevalence of asthma, allergic rhinitis, and atopic dermatitis among the Korean population, 2008–2017. *Clin Exp Pediatr* 2020; 63: 278.
- [5] Pols DH, Bohnen AM, Nielen MM, Korevaar JC, Bindels PJ. Risks for comorbidity in children with atopic disorders: an observational study in Dutch general practices. *BMJ open* 2017; 7: e018091.

- [6] Gilaberte Y, Pérez-Gilaberte JB, Poblador-Plou B, Bliiek-Bueno K, Gimeno-Miguel A, Prados-Torres A. Prevalence and comorbidity of atopic dermatitis in children: a large-scale population study based on real-world data. *J Clin Med* 2020; 9: 1632.
- [7] Huang AH, Roh YS, Sutaria N, Choi J, Williams KA, Canner JK, et al. Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States. *J Am Acad Dermatol* 2021; 85: 893–900.
- [8] Dharmage SC, Lowe A, Matheson MC, Burgess J, Allen K, Abramson MJ. Atopic dermatitis and the atopic march revisited. *Allergy* 2014; 69: 17–27.
- [9] Harris M, Chung F. Complications of general anesthesia. *Clin Plast Surg* 2013; 40: 503–513.
- [10] Stepanovic B, Sommerfield D, Lucas M, von Ungern-Sternberg BS. An update on allergy and anaphylaxis in pediatric anesthesia. *Paediatr Anaesth* 2019; 29: 892–900.
- [11] Kim JC, Kim DC, Choi YW, Lee ES, Choi JW. Association of chronic spontaneous urticaria with the first exposure to general anaesthesia. *Clin Exp Allergy* 2022; 52: 990–993.
- [12] Kuo H-C, Yang Y-L, Ho S-C, Guo MM-H, Jiang J-H, Huang Y-H. General anesthesia exposure in early life reduces the risk of allergic diseases: a nationwide population-based cohort study. *Medicine* 2016; 95: e4269.
- [13] Palacios AS, Ponce MO, Pérez AR, Medina FS, Marrero JG. Modification of mediators of immune reaction after general anaesthesia. *Allergol Immunopathol (Madr)* 2004; 32: 352–360.
- [14] Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. *Int J Epidemiol* 2017; 46: e15.
- [15] Yoon J, Choi JW. Primary cicatricial alopecia in a single-race Asian population: a 10-year nationwide population-based study in South Korea. *J Dermatol* 2018; 45: 1306–1311.
- [16] Soh BW, Kim SM, Kim YC, Choi GS, Choi JW. Increasing prevalence of alopecia areata in South Korea. *J Dermatol* 2019; 46: e331–e332.
- [17] Kim JC, Lee ES, Choi JW. Impact of alopecia areata on psychiatric disorders: a retrospective cohort study. *J Am Acad Dermatol* 2020; 82: 484–486.
- [18] 18. Kim JC, Choi JW. Impact of alopecia areata on subsequent pregnancy rate: a retrospective cohort study. *Australas J Dermatol* 2021; 62: e121–e123.
- [19] Lee H, Kim YC, Choi JW. Alopecia areata is not a risk factor for heart diseases: a 10-year retrospective cohort study. *PLoS One* 2021; 16: e0250216.
- [20] Sundararajan V, Quan H, Halfon P, Fushimi K, Luthi JC, Burnand B, et al. Cross-national comparative performance of three versions of the ICD-10 Charlson index. *Med Care* 2007; 45: 1210–1215.
- [21] Tzong KY, Han S, Roh A, Ing C. Epidemiology of pediatric surgical admissions in US children: data from the HCUP kids inpatient database. *J Neurosurg Anesthesiol* 2012; 24: 391–395.
- [22] von Ungern-Sternberg BS, Boda K, Chambers NA, Rebmann C, Johnson C, Sly PD, et al. Risk assessment for respiratory complications in paediatric anaesthesia: a prospective cohort study. *The Lancet* 2010; 376: 773–783.
- [23] Ko W-R, Huang J-Y, Chiang Y-C, Nfor ON, Ko P-C, Jan S-R, et al. Risk of autistic disorder after exposure to general anaesthesia and surgery: a nationwide, retrospective matched cohort study. *Eur J Anaesthesiol* 2015; 32: 303–310.
- [24] Tsai C-J, Lee CT-C, Liang SH-Y, Tsai P-J, Chen VC-H, Gossop M. Risk of ADHD after multiple exposures to general anesthesia: a nationwide retrospective cohort study. *J Atten Disord* 2018; 22: 229–239.
- [25] Feng Y-P, Yang T-S, Chung C-H, Chien W-C, Wong C-S. Early childhood general anesthesia exposure associated with later developmental delay: a national population-based cohort study. *PLoS One* 2020; 15: e0238289.
- [26] Ng YT, Chew FT. A systematic review and meta-analysis of risk factors associated with atopic dermatitis in Asia. *World Allergy Organ J* 2020; 13: 100477.
- [27] Mortz C, Andersen K, Dellgren C, Barington T, Bindslev-Jensen C. Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities. *Allergy* 2015; 70: 836–845.
- [28] Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. *J Allergy Clin Immunol* 2019; 143: 1–11.

- [29] Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. *The Lancet* 1999; 353: 196–200.
- [30] Kawamoto N, Kaneko H, Takemura M, Seishima M, Sakurai S, Fukao T, et al. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children. *Pediatr Allergy Immunol* 2006; 17: 125–133.
- [31] Jafarzadeh A, Hadavi M, Hassanshahi G, Rezaeian M, Vazirinejad R. General anesthetics on immune system cytokines: a narrative review article. *Anesth Pain Med* 2020; 10: e103033.
- [32] Lee J, Lozano-Ruiz B, Yang FM, Fan DD, Shen L, González-Navajas JM. The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy. *Front Immunol* 2021; 12: 625667.
- [33] Jin Z, Mendu SK, Birnir B. GABA is an effective immunomodulatory molecule. *Amino Acids* 2013; 45: 87–94.
- [34] Snider LA, Seligman LD, Ketchen BR et al. Tics and problem behaviors in schoolchildren: prevalence, characterization, and associations. *Pediatrics* 2002; 110: 331–336.
- [35] National Institute of Mental Health. Pediatric and Developmental Neuro-psychiatry Branch. <http://intramural.nimh.nih.gov/pdn/web.htm>, Posted January 26, 2005.
- [36] Swedo SE. Sydenham's chorea. A model for childhood autoimmune neuropsychiatric disorders. *JAMA* 1994; 272: 1788–1791.
- [37] Zai G, Bezchlibnyk YB, Richter MA et al. Myelin oligodendrocyte glycoprotein (MOG) gene is associated with obsessive-compulsive disorder. *Am J Med Genet B Neuropsychiatr Genet* 2004; 129B: 64–68.
- [38] Snider LA, Swedo SE. PANDAS: current status and directions for research. *Mol Psychiatry* 2004; 9: 900–907.
- [39] Lougee L, Perlmutter SJ, Nicolson R et al. Psychiatric disorders in first-degree relatives of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). *J Am Acad Child Adolesc Psychiatry* 2000; 39: 1120–1126.
- [40] Giedd JN, Rapoport JL, Leonard HL et al. Case study: acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy. *J Am Acad Child Adolesc Psychiatry* 1996; 35: 913–915.
- [41] Citak EC, Gucuyener K, Karabacak NI et al. Functional brain imaging in Sydenham's chorea and streptococcal tic disorders. *J Child Neurol* 2004; 19: 387–390.
- [42] Swedo SE, Leonard HL, Garvey M et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 Cases. *Am J Psychiatry* 1998; 155: 265–271.
- [43] van Toorn R, Weyers HH, Schoeman JF. Distinguishing PANDAS from Sydenham's chorea: case report and review of the literature. *Eur J Paediatr Neurol* 2004; 8: 211–216.
- [44] Snider LA, Sachdev V, MaCkaronis JE et al. Echocardiographic findings in the PANDAS subgroup. *Pediatrics* 2004; 114: 748–751.
- [45] Swedo SE, Grant PJ. Annotation: PANDAS: a model for human autoimmune disease. *J Child Psychol Psychiatry* 2005; 46: 227–234.
- [46] Storch EA, Gerdes AC, Adkins JW et al. Behavioral treatment of a child with PANDAS. *J Am Acad Child Adolesc Psychiatry* 2004; 43: 510–511.
- [47] Naguib M, Koorn R. Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. *CNS Drugs* 2002; 16: 229–247.
- [48] Kudoh A, Katagai H, Takase H et al. Effect of preoperative discontinuation of antipsychotics in schizophrenic patients on outcome during and after anaesthesia. *Eur J Anaesthesiol* 2004; 21: 414–416.
- [49] Coulter DM, Bate A, Meyboom RH et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. *BMJ* 2001; 322: 1207–1209.
- [50] Bookheimer S, Schrader LM, Rausch R et al. Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications. *Epilepsia* 2005; 46: 236–243.
- [51] Perlmutter SJ, Leitman SF, Garvey MA et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. *The Lancet* 1999; 354: 1153–1159.
- [52] Orvidas LJ, Slattery MJ. Pediatric autoimmune neuropsychiatric disorders and streptococcal infections: role of otolaryngologist. *Laryngoscope* 2001; 111: 1515–1519.

- [53] Murphy ML, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). *Arch Pediatr Adolesc Med* 2002; 156: 356–361.
- [54] Heubi C, Shott SR. PANDAS: pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections – an uncommon, but important indication for tonsillectomy. *Int J Pediatr Otorhinolaryngol* 2003; 67: 837–840.
- [55] Wood L, Jacobs P. The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels. *J Clin Apheresis* 1986; 3: 124–128.
- [56] Qudah AA, Shahar E, Logan WJ, Murphy EG. Neonatal Guillain-Barre syndrome. *Pediatr Neurol.* 1988;4(4):255–256. doi: 10.1016/0887-8994(88)90042-2.
- [57] Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barre syndrome. *J Pediatr.* 2003;142(3):305–309. doi: 10.1067/mpd.2003.115.
- [58] Bradshaw DY, Jones HR., Jr Guillain-Barre syndrome in children: clinical course, electrodiagnosis, and prognosis. *Muscle Nerve.* 1992;15(4):500–506. doi: 10.1002/mus.880150415.
- [59] Nguyen DK, Agenarioti-Belanger S, Vanasse M. Pain and the Guillain-Barre syndrome in children under 6 years old. *J Pediatr.* 1999;134(6):773–776. doi: 10.1016/S0022-3476(99)70297-0.
- [60] Roodbol J, de Wit MC, Walgaard C, de Hoog M, Catsman-Berrevoets CE, Jacobs BC. Recognizing Guillain-Barre syndrome in preschool children. *Neurology.* 2011;76(9):807–810. doi: 10.1212/WNL.0b013e31820e7b62.
- [61] Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. *Ann Neurol.* 1990;27(Suppl):S21–24. doi: 10.1002/ana.410270707.
- [62] Yikilmaz A, Doganay S, Gumus H, Per H, Kumandas S, Coskun A. Magnetic resonance imaging of childhood Guillain-Barre syndrome. *Childs Nerv Syst.* 2010;26(8):1103–1108. doi: 10.1007/s00381-010-1197-8.
- [63] Nagasawa K, Kuwabara S, Misawa S, Fujii K, Tanabe Y, Yuki N, Hattori T, Kohno Y. Electrophysiological subtypes and prognosis of childhood Guillain-Barre syndrome in Japan. *Muscle Nerve.* 2006;33(6):766–770. doi: 10.1002/mus.20520.
- [64] Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget.* 2018;9(6):7204–18. doi: 10.18632/oncotarget.23208.
- [65] Akdis CA. Therapies for allergic inflammation: Refining strategies to induce tolerance. *Nat Med.* 2012;18(5):736–49. doi: 10.1038/nm.2754.
- [66] Abbas AK, Lichtman AH, Pillai S. *Cellular and molecular immunology.* 8th ed. US: Elsevier Sanders; 2014.
- [67] Mahmoud K, Ammar A. Immunomodulatory effects of anesthetics during thoracic surgery. *Anesthesiol Res Pract.* 2011;2011:317410. doi: 10.1155/2011/317410.
- [68] Jafarzadeh A, Larussa T, Nemati M, Jalapour S. T cell subsets play an important role in the determination of the clinical outcome of *Helicobacter pylori* infection. *Microb Pathog.* 2018;116:227–36. doi: 10.1016/j.micpath.2018.01.040.
- [69] Nemati M, Malla N, Yadav M, Khorramdelazad H, Jafarzadeh A. Humoral and T cell-mediated immune response against trichomoniasis. *Parasite Immunol.* 2018;40(3) doi: 10.1111/pim.12510.
- [70] Kalayci D, Dikmen B, Kacmaz M, Taspinar V, Ornek D, Turan O. Plasma levels of interleukin-10 and nitric oxide in response to two different desflurane anesthesia flow rates. *Braz J Anesthesiol.* 2014;64(4):292–8. doi: 10.1016/j.bjane.2013.06.008.
- [71] Jafarzadeh A, Shokri F. The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates. *Clin Exp Immunol.* 2003;131(3):451–6. doi: 10.1046/j.1365-2249.2003.02093.
- [72] Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. *Injury.* 2007;38(12):1336–45. doi: 10.1016/j.injury.2007.10.003.
- [73] Pirbudak Cocelli L, Ugur MG, Karadasli H. Comparison of effects of low-flow sevoflurane and desflurane anesthesia on neutrophil and T-cell populations. *Curr Ther Res Clin Exp.* 2012;73(1-2):41–51. doi: 10.1016/j.curtheres.2012.02.005.

- [74] Gong L, Qin Q, Zhou L, Ouyang W, Li Y, Wu Y, et al. Effects of fentanyl anesthesia and sufentanil anesthesia on regulatory T cells frequencies. *Int J Clin Exp Pathol*. 2014;7(11):7708–16.
- [75] Alsina E, Matute E, Ruiz-Huerta AD, Gilsanz F. The effects of sevoflurane or remifentanil on the stress response to surgical stimulus. *Curr Pharm Des*. 2014;20(34):5449–68. doi: 10.2174/1381612820666140325105723.
- [76] Brown EN, Lydic R, Schiff ND. General anesthesia, sleep, and coma. *N Engl J Med*. 2010;363(27):2638–50. doi: 10.1056/NEJMra0808281.
- [77] Miller RD. *Miller's anesthesia*. Philadelphia: Elsevier; 2015.
- [78] Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. *Anesth Analg*. 2003;97(5):1331–9. doi: 10.1213/01.ane.0000082995.44040.07.
- [79] Schneemilch CE, Hachenberg T, Ansorge S, Ittenson A, Bank U. Effects of different anaesthetic agents on immune cell function in vitro. *Eur J Anaesthesiol*. 2005;22(8):616–23. doi: 10.1017/s0265021505001031.
- [80] Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. *Br J Anaesth*. 2010;105(2):106–15. doi: 10.1093/bja/aeq164.
- [81] Welters ID, Hafer G, Menzebach A, Muhling J, Neuhauser C, Browning P, et al. Ketamine inhibits transcription factors activator protein 1 and nuclear factor-kappaB, interleukin-8 production, as well as CD11b and CD16 expression: studies in human leukocytes and leukocytic cell lines. *Anesth Analg*. 2010;110(3):934–41. doi: 10.1213/ANE.0b013e3181c95cfa.